Our Global Leadership Team
Our executive team is drawn from the leadership of Stallergenes and Greer together with external biopharmaceutical talent. Together they form a forward-thinking and collaborative multi-cultural group dedicated to leading our employees and partners toward our vision of worldwide freedom from allergy.
Chairman and CEO Stallergenes Greer
Mr. Firouz has 27 years pharmaceutical industry experience and was President and CEO of EMD Serono, Inc. and Head of the Global Business Unit Fertility and Endocrinology franchise. He was also a member of the Executive Management Board of Merck Serono.
From 2001 to 2003, Mr. Firouz was Executive Vice President, Reproductive Health North America, and from 1998 to 2001, he was Vice President, Latin America for Serono S.A.
He is a past Board Member of the Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organization (BIO), and the Massachusetts Biotech Council (MBC).
Mr. Firouz received a Bachelor of Arts in Political Science from George Washington University. He has participated in executive MBA programs at the Kellogg Business School and Babson College.
Chief Financial Officer
A Swiss national, Peter Bühler trained as a Swiss Certified Accountant complemented by an MBA from SBS (Swiss Business School). He has more than 20 years extensive international experience in Finance, including 12 years in the healthcare industry (Anteis, Merck Serono and Eli Lilly).
From 2010 to 2013 he was Finance Director Europe for Logitech. Since April 15, 2013 he was Chief Financial Officer and member of the Executive Committee of Stallergenes. Peter Bühler serves now as Group Chief Financial Officer.
Executive Vice President, Head of Europe & International, President of Stallergenes SAS
Michele Antonelli has more than 20 years of international experience in the biopharmaceutical industry with extensive expertise in both manufacturing and commercial.
He joined Stallergenes SAS in November 2015 as Executive Vice President, Head of International Operations. Michele previously worked at UCB where he held roles of various responsibility and scope, most recently serving as Executive Vice President and Head of lmmunology Europe, overseeing the region’s commercial, medical, and market access activities. Prior to joining UCB, Michele spent 16 years at Merck Serono, ultimately serving as Senior Vice President and Global Head of Biotech Manufacturing and Process Development.
Executive Vice President, Head Of Americas, President & CEO Stallergenes Greer Inc.
Richard (Rick) Russell
Richard (Rick) Russell will lead the Americas for Stallergenes Greer. He has more than 20 years of experience leading commercial operations and in developing and implementing sales and marketing activities for major pharmaceutical brands in North America and the European Union.
His pharmaceutical experience spans many therapeutic areas ranging from central nervous system (CNS) disorders, women’s health, cardiovascular disease and neurodegenerative disorders. Most recently, Rick was Chief Commercial Officer at Sunovion, where he led commercial operations for a portfolio of eight products generating $1.5 billion in revenue. Previously, he was the U.S. Executive Vice President, Neurodegenerative Diseases and Rheumatology at EMD Serono, where he managed all sales and marketing activities for the multiple sclerosis franchise. Earlier in his career, Rick was Vice President, Marketing at Sanofi-Aventis, and has held several roles in sales and marketing leadership. He is a graduate of Bates College and the University of New Hampshire
General Counsel and Company Secretary
Devin Smith joined the company from EMD Serono, Inc., the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. At EMD Serono, Devin Smith lead the North American legal department as Vice President and General Counsel.
Prior to EMD Serono, Devin Smith was an associate lawyer and then partner at the international law firm of Nixon Peabody LLP, where he represented emerging and established life science, information technology and manufacturing businesses.
Devin Smith received his law degree (cum laude) from Suffolk University Law School and a B.A. in political science from the University of North Carolina - Chapel Hill.